This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignees: Boehringer Ingelheim International Gmbh, Cdr-Life Ag, Novartis Ag. Active years: 2024-2025.
Company Filing History:
1 out of 1,560 
1 out of 4 
1 out of 3,974 
Years Active: 2024-2025
Title: Christian Leisner: Innovator in Ocular Disease Treatment
Introduction
Christian Leisner is a notable inventor based in Thalwil, Switzerland. He has made significant contributions to the field of ocular disease treatment through his innovative patents. With a total of 2 patents, Leisner's work focuses on advancing therapeutic methods for eye-related disorders.
Latest Patents
Leisner's latest patents include groundbreaking inventions such as "Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases." This invention relates to antibodies that specifically target complement C3, providing new methods for treating various diseases or disorders. Another significant patent is titled "Methods of treating dry eye disease using TNF alpha antagonists." This disclosure presents novel predictive methods and personalized therapies for treating dry eye disease (DED). It emphasizes the selective administration of TNFα antagonists, such as LME636, based on a patient's genetic predisposition to respond favorably to the treatment.
Career Highlights
Throughout his career, Christian Leisner has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable organizations include Cdr-life AG and Boehringer Ingelheim International GmbH. His experience in these companies has contributed to his expertise in developing innovative treatments for ocular diseases.
Collaborations
Leisner has collaborated with various professionals in his field, including Leonardo Borras and Pankaj Gupta. These collaborations have further enhanced his research and development efforts in ocular therapeutics.
Conclusion
Christian Leisner's contributions to the field of ocular disease treatment through his innovative patents demonstrate his commitment to advancing medical science. His work continues to pave the way for new therapeutic approaches that can significantly improve patient outcomes.